passages: 2329
passages: document
passages: Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults . A new immunomodulating agent , bestatin ( INN : Ubenimex has low toxicity even after long-term oral administration and has significant modifications in immunological response . A cooperative randomized controlled study of bestatin immunotherapy in combination with remission maintenance chemotherapy for adult acute nonlymphocytic leukemia ( ANLL ) was performed . After induction of complete remission , patients were randomized to the bestatin group ( 30 mg/bw per os ( po ) daily ) and the control group . The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the bestatin group achieved longer remission than the control group and a statistically significant longer survival . Though this prolongation of remission was not significant in the bestatin group compared to the control group in the 15-49 yr age group , in the 50-65 yr age group it was significantly longer . Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has prolonged survival and remission especially in elderly patients , with few side-effects .
entities: 2330
entities: Intervention_Pharmacological
entities: bestatin
entities: 2331
entities: Intervention_Pharmacological
entities: bestatin
entities: 2332
entities: Intervention_Pharmacological
entities: bestatin
entities: 2333
entities: Intervention_Pharmacological
entities: bestatin
entities: 2334
entities: Intervention_Pharmacological
entities: bestatin
entities: 2335
entities: Intervention_Pharmacological
entities: bestatin
entities: 2336
entities: Intervention_Pharmacological
entities: bestatin
entities: 2337
entities: Intervention_Pharmacological
entities: Bestatin
entities: 2338
entities: Outcome_Physical
entities: remission
entities: 2339
entities: Outcome_Mortality
entities: survival .
entities: 2340
entities: Outcome_Physical
entities: prolongation of remission
entities: 2341
entities: Outcome_Mortality
entities: survival
entities: 2342
entities: Outcome_Mortality
entities: remission
entities: 2343
entities: Outcome_Adverse-effects
entities: side-effects .
entities: 2344
entities: Participant_Condition
entities: acute nonlymphocytic leukemia
entities: 2345
entities: Participant_Age
entities: adults
entities: 2346
entities: Participant_Age
entities: adult
entities: 2347
entities: Participant_Condition
entities: acute nonlymphocytic leukemia ( ANLL )
entities: 2348
entities: Participant_Sample-size
entities: 101
entities: 2349
entities: Participant_Sample-size
entities: 48
entities: 2350
entities: Participant_Sample-size
entities: 53